Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
EBITDA as a percentage of revenue
Latest
-34.88%
↓ 86% vs avg
Percentile
P17
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
-18.77%
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| TTM | -34.88% | +63.9% |
| 2024 | -96.52% | - |
| 2023 | 0.00% | - |
| 2022 | 0.00% | - |
| 2021 | 0.00% | - |
| 2020 | 0.00% | - |
| 2019 | 0.00% | - |